Will the U.S. FDA Authorize a Protein-Based COVID-19 Vaccine?

In COVID-19, Latest News by Precision Vaccinations

When the U.S. FDA’s vaccine committee endorsed the Maryland-produced protein-based COVID-19 vaccine on June 7, 2022, many people expected authorization would immediately follow.
However, according to Novavax Inc.’s statement issued on July 1, 2022, this World Health Organization Listed vaccine remains under FDA review.
Novavax stated ‘it is awaiting U.S. emergency use authorization (EUA) for our prototype COVID-19 vaccine, and we are committed to bringing it to market.

Read More